You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
-
Self-Supervised Training in Geospatial Applications with a Robust Hierarchical Vision Transformer (STAR)
SBC: UNIVERSITY TECHNICAL SERVICES INC Topic: OSD22A001Satellite Imagery in Geospatial Intelligence (GEOINT), in conjunction with imagery intelligence (IMINT), geospatial information, and other means of gaining intelligence, has greatly improved the potential of the warfighter and decision makers enabling them to gain a more comprehensive perspective, an in-depth understanding, and a cross-functional awareness of the operational environment. The Artif ...
STTR Phase I 2022 Department of DefenseNational Geospatial-Intelligence Agency -
Urocortin-2 Gene Transfer for Type 1 Diabetes and Associated LV Dysfunction
SBC: Renova Therapeutics, Inc. Topic: NHLBIABSTRACT Type-1 Diabetes Mellitus (T1DM) affects 1.25 million patients in US with 40,000 new patients annually. Lifespan is shortened 11-13 years, due to kidney and heart disease. Tight glucose control reduces microvascular complications and adverse cardiovascular events. Insulin therapy is essential for such patients, but has shortcomings: a) only 1 in 3 patients achieve targeted glucose control ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Preclinical testing of a 3D printed external scaffold device to prevent vein graft failure after coronary bypass graft surgery
SBC: BIOGRAFT, INC. Topic: NHLBISaphenous vein graft (SVG) failure following coronary artery bypass grafting (CABG) is a critical clinical problem, with recent studies revealing that as many as 25% of vein grafts develop stenosis within 12-18 months after surgery, and up to 50% of grafts occlude within 5-10 years. CABG surgery is the gold standard treatment for patients with severe multi-vessel disease, with over 370,000 procedu ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Assessment of mobile application-delivered lighting interventions for reducing circadian disruption in shift workers
SBC: ARCASCOPE INC Topic: NHLBIPROJECT SUMMARY Shift workers experience profound circadian disruption, which can have deleterious long term effects on their health and quality of life. Mood, fatigue, and performance can be improved in shift workers by moving the timing of their peak circadian drive to sleep outside the hours they are expected to work. This can be achieved with a targeted lighting intervention, as light is the p ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
A novel vaccine against mosquito-borne Zika virus based on mosquito salivary gland protein AgBR1
SBC: L2 Diagnostics, LLC Topic: NIAIDSUMMARY Arboviruses present a constant threat to human and animal health worldwide. They are transmitted by hematophagous arthropods, primarily mosquitoes. One of them, Aedes aegypti, is the primary vector of several widely spread arboviruses such as Zika, dengue and West Nile viruses, and for most of them, human-licensed vaccines do not exist or are suboptimal. These pathogens are transmitted int ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
A rapid test for congenital syphilis screening
SBC: MelioLabs Inc. Topic: NICHDPROJECT SUMMARY Since 2014, Congenital Syphilis (CS) cases in the United States, caused by the transplacental transmission of the bacterium Treponema pallidum from mother to child, have increased at an alarming rate. Targeted surveillance studies indicate a rise andgt;185% from 2014 to 2018 alone. Women who acquire syphilis within 4 years of pregnancy will transmit the infection to 80% of their fe ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Solving Sepsis: Early Identification and Prompt Management Using Machine Learning
SBC: Cohere-Med, Inc. Topic: 300Abstract This fast-track STTR application proposes to enhance, validate, and scale Sepsis Watch, a deep learning sepsis detection and management system built using data from the Emergency Department (ED) Duke University Hospital (DUH). The proposal will extend and enhance Sepsis Watch to EDs, general inpatient wards, and intensive care unit (ICU) settings across multiple health systems in the Unit ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Design and Engineering of Biodegradable 3D Nanoprinted Microcarriers for HIV Drug Delivery
SBC: INFRATRAC INC Topic: NIAIDPrecise, customizable drug delivery remains a long-term goal, for HIV in particular, as such technologies would allow therapies tailored to a patient’s biological makeup and potentially improve adherence. Extended-release methods address part of the issue, but face limitations. A novel drug delivery system could offer better pediatric dosing, via both oral and new routes of administration. Exist ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Developing Vertebrate-Specific Replication-Defective Dengue Virus as Novel Single-CycleDengue Vaccine Candidate
SBC: Tengen Biomedical Co Topic: NIAIDDeveloping Vertebrate-Specific Replication-Defective Dengue Virus asa Novel Single-Cycle Dengue Vaccine Candidate Abstract With an estimated minimum of 390 million dengue virus (DENV) infections per year, the DENV epidemic was listed as one of the worldandapos;s top 10 public health threats by WHO in 2019. At present, there is no specific treatment. A universal vaccine is urgently needed. DENV vac ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Development of a Gectosome Therapy for Cardiovascular Diseases
SBC: Vesicle Therapeutics Inc. Topic: NHLBIProject Summary Vesicle Therapeutics Inc aims to develop and commercialize a new therapy for homozygous familial hypercholesterolemia (hoFH). A majority of hoFH is caused by mutations in both alleles of the gene encoding the LDL receptor (LDLR). Since the efficacy of both statins and PCSK9 antibody therapies largely depends on functional LDL receptors, patients with hoFH show limited responses to ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health